Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer

NCT05911217 is registered in ClinicalTrials.gov with CARsgen Therapeutics Co., Ltd. as lead sponsor.

NCT NCT05911217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05911217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic Cancer
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 11, 2023
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer